Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks
Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.
How this was made
The 30-second read
Why it matters
Earnings beats and guidance raises for EVH and GDRX provide clear buying opportunities, while ASTH's miss may trigger profit‑taking. TNDM's in‑line results suggest limited upside.
Market read
The earnings releases provide fresh, material data that can drive short‑term trading decisions across the healthcare‑tech space.
What to watch
Potential regulatory changes in telehealth reimbursement could affect future profitability across the sector.
Background
The article compares Q2 earnings of four publicly traded healthcare‑technology companies, highlighting revenue growth, earnings beats/misses, and guidance updates.
Ticker impact
Evolent Health reported Q2 revenue of $652.5M, a 46.9% YoY increase, beating analyst estimates and raising full-year guidance.
Potential continued rally, target +15% over next 2 weeks.
Revenue beat, guidance raise, and 60% stock gain since release indicate strong market reaction.
Astrana Health posted Q2 revenue of $972.5M, up 48.5% YoY but missed earnings estimates by 1.3% and gave slightly weaker guidance.
Possible short-term pullback of 5-8% as investors reassess earnings outlook.
Revenue growth is strong, but earnings miss and weaker guidance could dampen sentiment.
Tandem Diabetes reported Q2 revenue of $254.6M, up 5.8% YoY, in line with expectations, and met full-year guidance.
Sideways trading expected, +/-2% range.
No surprise in earnings or guidance, so limited new catalyst.
GoodRx posted Q2 revenue of $200.4M, down 1.3% YoY but topped earnings expectations by 3.5% and raised full-year revenue and EBITDA guidance.
Potential upside of 8-12% as market digests stronger guidance.
Guidance lift and earnings beat offset modest revenue decline, providing a bullish catalyst.
Market effects
Healthcare technology sector shows strong top‑line growth, but earnings quality varies across peers.
U.S. healthcare‑tech stocks may see divergent moves as investors reprice earnings beats versus misses.
Results highlight the broader trend of digital health adoption worldwide.
Counterpoint
Despite revenue growth, the earnings miss at Astrana Health could signal overvaluation; a short position may be justified.
Key entities
- CompanyEvolent Health
Provider of specialty care management services and technology solutions.
- CompanyAstrana Health
Technology‑powered healthcare platform focused on value‑based care.
- CompanyTandem Diabetes
Developer of automated insulin delivery systems.
- CompanyGoodRx
Digital platform for prescription drug price comparison.
